Tilray Brands (NASDAQ:TLRY) Shares Gap Up – Still a Buy?

Tilray Brands, Inc. (NASDAQ:TLRY)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $7.87, but opened at $9.30. Tilray Brands shares last traded at $7.7560, with a volume of 18,212,858 shares.

More Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Federal rescheduling reports and Tilray’s own statement that it’s “positioned” to expand in the U.S. led investors to price in a much larger addressable market and faster medical access for patients. Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
• Positive Sentiment: Sector headlines and momentum pieces triggered a quick rally in cannabis names; Tilray was singled out in multiple write-ups and jumped on early buying interest. Tilray Surges 10%: Rescheduling Momentum Builds as Traders Await Official Confirmation
• Positive Sentiment: Unusually large call buying (reported ~45,000 contracts) and bullish analyst notes (e.g., Roth Capital forecasting sizable upside) amplified the move by attracting short-term, speculative demand and options-driven hedging flows. 1 Wall Street Analyst Says Tilray Stock Could Jump Over 40%
• Positive Sentiment: Corporate execution news — BrewDog US (a Tilray brand) rolled out new seasonal product initiatives, reinforcing consumer-beverage growth avenues beyond cannabis. BrewDog USA Doubles Down on Headliners
• Neutral Sentiment: Trading was briefly halted under an LULD pause (mechanical volatility control) during the run-up — indicates rapid price movement but is procedural rather than a new catalyst.
• Negative Sentiment: Insider selling: Director David Hopkinson sold 33,556 shares (avg. $6.94) earlier this week; while such sales can be routine, they create a counter-narrative for some investors. Form 4 — David G. Hopkinson Sale

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. Roth Mkm upgraded shares of Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a report on Thursday, April 2nd. Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Finally, TD Cowen decreased their price objective on shares of Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a report on Monday, March 30th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $11.50.

Tilray Brands Stock Down 4.0%

The business’s fifty day moving average is $7.04 and its two-hundred day moving average is $9.53. The company has a market cap of $880.99 million, a P/E ratio of -0.56 and a beta of 2.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.66 and a current ratio of 2.79.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.10). Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. The company had revenue of $206.73 million for the quarter, compared to the consensus estimate of $201.35 million. During the same quarter in the previous year, the business earned ($0.87) EPS. Equities analysts predict that Tilray Brands, Inc. will post -0.55 EPS for the current year.

Insiders Place Their Bets

In related news, Director David G. Hopkinson sold 33,556 shares of Tilray Brands stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $6.94, for a total transaction of $232,878.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.84% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Tidal Investments LLC increased its position in Tilray Brands by 15.0% during the 2nd quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock valued at $12,006,000 after purchasing an additional 3,776,410 shares during the period. Millennium Management LLC increased its position in Tilray Brands by 281.0% during the 3rd quarter. Millennium Management LLC now owns 4,942,319 shares of the company’s stock valued at $8,550,000 after purchasing an additional 3,645,060 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tilray Brands during the 3rd quarter valued at about $5,813,000. Ausdal Financial Partners Inc. purchased a new position in Tilray Brands during the 2nd quarter valued at about $939,000. Finally, Swiss National Bank increased its position in Tilray Brands by 4.4% during the 3rd quarter. Swiss National Bank now owns 2,013,038 shares of the company’s stock valued at $3,483,000 after purchasing an additional 84,900 shares during the period. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.